Marinus Pharmaceuticals Inc at 38th Annual J.P Morgan Healthcare Conference Transcript
Good morning, everyone. Thanks for coming. My name is Rumen Vasilev, and I'm a member of the JPMorgan team. It is my pleasure to introduce the CEO of Marinus, Scott Braunstein.
Well, good morning, and thank you all for coming. It's Thursday. I know it's been a long week for many of us. It's raining outside, so thrilled to have you here today. And I'm going to jump right in because we have quite a bit of material to cover.
That's our forward-looking statement, and you can find that on our website.
And let me start by telling you a little bit about our company, Marinus Pharmaceuticals. We have been studying ganaxolone, a GABA modulator, for many years. But since taking over the company a little less than a year ago as executive chairman and now CEO, we are focusing our efforts in the epilepsy space. We are fortunate enough to have several formulations of ganaxolone, both IV and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |